|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||51.34 - 51.61|
|52 Week Range||44.30 - 78.45|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||13.45|
|Forward Dividend & Yield||0.85 (1.63%)|
|Ex-Dividend Date||Sep 29, 2022|
|1y Target Est||59.00|
Subscribe to Yahoo Finance Plus to view Fair Value for FUJIY
FUJIFILM (FUJIY) second-quarter performance gains from strong revenue growth in Medical Systems, Electronic Materials and Imaging business segment.
Fujifilm Holdings Corp. said it was giving up on its antiviral drug Avigan to treat Covid-19, more than two years after Japan’s prime minister hailed the pill.
Fujifilm Holdings Corp (OTC: FUJIY) (OTC: FUJIF) has discontinued the development of its anti-influenza drug, Avigan (favipiravir), for use as a therapeutic drug against COVID-19. In 2021, Fujifilm Toyama Chemical began a phase 3 clinical trial in Japan with a target enrollment of 316 subjects to confirm Avigan's efficacy in preventing the progression to severe symptoms in COVID-19 patients who have not yet been vaccinated. However, enrollment was terminated at 84 subjects in March 2022 followin